JPM26: What’s in a biopharma? CEO says Teva has the goods In 2023, Teva made a pledge to bolster its innovative medicines portfolio without leaving behind its century-long legacy as a leading generics drugmaker. | Under CEO Richard Francis, Teva has long bee...

#JPM26 #biopharma #Teva #TevaPharmaceuticals #RichardFrancis #innovativemedicines #generics #biopharmaidentity #PivottoGrowth #RoyaltyPharma #TEV408 #vitiligo #phase2bstudy #genericmedicines #schizophrenia #olanzapine #Uzedy #longactingmedication #biosimilars #biosimilarmarket
zurl.co/ErF5t